Conference item icon

Conference item : Abstract

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study

Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Files:
Publisher copy:
10.1136/annrheumdis-2021-eular.474

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Oxford college:
St Peter's College
Role:
Author
ORCID:
0000-0001-7766-6167
Publisher:
BMJ Publishing Group
Journal:
Annals of the Rheumatic Diseases More from this journal
Volume:
80
Issue:
S1
Article number:
POS0653
Pages:
566-567
Publication date:
2021-05-19
Acceptance date:
2021-04-01
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Language:
English
Keywords:
Subtype:
Abstract
Pubs id:
1189643
Local pid:
pubs:1189643
Deposit date:
2021-08-04

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP